title: Effect of salvianolic acid A and C compatibility on inflammatory cytokines in rats with unilateral ureteral obstruction.
abstract: OBJECTIVE
  To investigate the effect of salvianolic acid A and C component molecules, which are involved in drug compatibility, on inflammatory cytokine expression that affects human chemokine ligand 5 (CCL5) and chemokine ligand 10 (CXCL10) levels in rats with unilateral ureteral obstruction (UUO).
  
  
  METHODS
  Fifty Sprague Dawley rats were randomly divided into five groups: normal, model, salvianolic acid A, salvianolic acid C and salvianolic acid A and C groups. The normal group was used as the control, and the other groups of rats had a UUO model established. The control group had free access to food and water, and the other groups received the corresponding drugs for 2 weeks. After the last administration, urine β2-microglobulin (β 2-MG) and N-acetyl-β-D-glucosaminidase (NAG) levels were analyzed. After 24 h, all rats were sacrificed and the serum was analyzed for creatinine (Cr) and blood urea nitrogen (BUN) levels. Rat kidneys were removed, and CCL5 and CXCL10 inflammatory cytokine mRNA expression was measured using real-time fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR). Kidney fibrosis was observed using hematoxylin-eosin (HE) staining and Masson trichrome staining.
  
  
  RESULTS
  In the salvianolic acid A and salvianolic acid C treatment groups, serum Cr and urine NAG levels were significantly lower than in the model group (both P < 0.05). In all treatment groups, urine β2-MG levels were significantly lower than in the model group (all P < 0.05). Compared with model group, the pathological changes and collagen deposition improved to varying degrees (both P < 0.05). CCL5 and CXCL10 mRNA expression decreased to different degrees compared with the model group (both P < 0.05).
  
  
  CONCLUSIONS
  Salvianolic acid A and C are component molecules of drug compatibility, and they may protect renal function and improve tubular function and renal pathology to a certain degree in UUO. This improvement may be related to a reduction in inflammatory cytokines CCL5 and CXCL10 secretion in the UUO rat kidney.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Tong
authors.initials: T
authors.lastname: Gu
authors.forename: Xu
authors.initials: X
authors.lastname: Fu
authors.forename: Renjie
authors.initials: R
authors.lastname: Zhao
mesh_terms: D000475:Alkenes / Q000008:administration & dosage*; D000818:Animals; D002109:Caffeic Acids / Q000008:administration & dosage*; D018946:Chemokine CCL5 / Q000235:genetics / Q000276:immunology; D054357:Chemokine CXCL10 / Q000235:genetics / Q000276:immunology; D016207:Cytokines / Q000235:genetics / Q000276:immunology*; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D006801:Humans; D007773:Lactates / Q000008:administration & dosage*; D008297:Male; D059808:Polyphenols / Q000008:administration & dosage*; D051381:Rats; D014517:Ureteral Obstruction / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D001572:Benzofurans
chemical_list: D000475:Alkenes; D002109:Caffeic Acids; D018946:Chemokine CCL5; D054357:Chemokine CXCL10; D016207:Cytokines; D004365:Drugs, Chinese Herbal; D007773:Lactates; D059808:Polyphenols; C066201:salvianolic acid A; C000597819:salvianolic acid C; D001572:Benzofurans